Plasma is a blood element, derived from whole blood by plasmapheresis, and used for several therapeutic and medical applications. Human plasma is a source of numerous different proteins, however only few of these proteins are useful for producing therapeutic plasma products. The process of separation, extraction and sanitization of these proteins from the plasma is called as fractionation process. Plasma fractionation is a process of mining various components of blood-derived plasma. It acts as nature’s raw material which is used in dozens of life-saving treatments and medications. The process of plasma fractionation is used to treat protein deficiency disorders in the healthcare sector. The main function of plasma fractionation is to remove or inactivate the virus and prions. Plasma covers various proteins including immunoglobulins, albumin, and clotting proteins such as fibrinogen. Among these albumin constitutes about 60% of the total protein in plasma and is present at concentrations between 35 and 55 mg/ml. It is the important factor responsible to the osmotic pressure of the blood and it functions as a carrier molecule for molecules with low water solubilities such as lipid-soluble hormones, pharmaceutical compounds, enzymes, metal ions, and fatty acids. The increasing frequency of respiratory diseases and alpha-1 antitrypsin deficiency along with growing geriatric population, increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the development of the plasma fractionation market.
Global Plasma Fractionation market is segmented based on the Application as Immunology, Hematology, Critical Care, Rheumatology. On the basis of Product, the global Plasma Fractionation market is segregated as Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor. The report segments global Plasma Fractionation market based on End User (Hospital, Clinic, Academic Institute.
Global Plasma Fractionation market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional Plasma Fractionation market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Research Methodology:
To calculate the market size, the report considers the revenue generated from the sales of Plasma Fractionation market manufacturers. The revenue generated from the sales of Plasma Fractionation manufacturer has been calculated through primary and secondary research.
The market size estimation also considered leading players revenues as part of triangulation The key players considered are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products in the Plasma Fractionation market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes types of segmentation determined using secondary sources and verified through primary sources.
The Plasma Fractionation Market has been segmented as below:
Plasma Fractionation Market, By Application
Plasma Fractionation Market, By Product
Plasma Fractionation Market, By End User
Plasma Fractionation Market, By Region
Report scope:
The global Plasma Fractionation market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends. The report scope includes market analysis on regional as well as country level.
Reasons to Buy this Report:
Below are our New Reports :-
Technologies for Long-term Care and Home Healthcare Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Market Research Process
2.3. Research Data Analysis
2.3.1. Secondary Research
2.3.2. Primary Research
2.3.3. Models for Estimation
2.4. Market Size Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
3. Executive Summary
4. Plasma Fractionation Market, By Product
4.1. Key Points
4.2. Albumin
4.2.1. Market Overview
4.2.2. Market Size & Forecast
4.3. Protease Inhibitors
4.3.1. Market Overview
4.3.2. Market Size & Forecast
4.4. Other Products
4.4.1. Market Overview
4.4.2. Market Size & Forecast
4.5. Immunoglobulins
4.5.1. Intravenous Immunoglobulins
4.5.1.1. Market Overview
4.5.1.2. Market Size & Forecast
4.5.2. Subcutaneous Immunoglobulins
4.5.2.1. Market Overview
4.5.2.2. Market Size & Forecast
4.5.3. Other Immunoglobulins
4.5.3.1. Market Overview
4.5.3.2. Market Size & Forecast
4.6. Coagulation Factor Concentrates
4.6.1. Factor VIII
4.6.1.1. Market Overview
4.6.1.2. Market Size & Forecast
1.1.1. Factor IX
1.1.1.1. Market Overview
1.1.1.2. Market Size & Forecast
1.1.2. Von Willebrand Factor
1.1.2.1. Market Overview
1.1.2.2. Market Size & Forecast
1.1.3. Prothrombin Complex Concentrate
1.1.3.1. Market Overview
1.1.3.2. Market Size & Forecast
1.1.4. Fibrinogen Concentrates
1.1.4.1. Market Overview
1.1.4.2. Market Size & Forecast
1.1.5. Factor XIII
1.1.5.1. Market Overview
1.1.5.2. Market Size & Forecast
2. Plasma Fractionation Market, By Offering
2.1. Key Points
2.2. Probes
2.2.1. Market Overview
2.2.2. Market Size & Forecast
2.3. Software
2.3.1. Market Overview
2.3.2. Market Size & Forecast
2.4. Atomic Force Microscopes
2.4.1. Contact Mode
2.4.1.1. Market Overview
2.4.1.2. Market Size & Forecast
2.4.2. Non-Contact Mode
2.4.2.1. Market Overview
2.4.2.2. Market Size & Forecast
2.4.3. Tapping Mode
2.4.3.1. Market Overview
2.4.3.2. Market Size & Forecast
3. Plasma Fractionation Market, By End User
3.1. Key Points
3.2. Academic Institutes
3.2.1. Market Overview
3.2.2. Market Size & Forecast
3.3. Clinical Research Laboratories
3.3.1. Market Overview
3.3.2. Market Size & Forecast
3.4. Hospitals & Clinics
3.4.1. Market Overview
3.4.2. Market Size & Forecast
4. Plasma Fractionation Market, By Region
4.1. North America
4.1.1. North America Industrial Floor Coating, By Product
4.1.2. North America Industrial Floor Coating, By Offering
4.1.3. North America Industrial Floor Coating, By End User
4.1.4. By Country
4.1.4.1.1. U.S
4.1.4.1.2. Canada
4.1.4.1.3. Mexico
4.2. Europe
4.2.1. Europe Industrial Floor Coating, By Product
4.2.2. Europe Industrial Floor Coating, By Offering
4.2.3. Europe Industrial Floor Coating, By End User
1.1.1. By Country
4.2.3.1.1. U.K
4.2.3.1.2. Germany
4.2.3.1.3. Italy
4.2.3.1.4. France
4.2.3.1.5. Rest of Europe
4.3. Asia Pacific
4.3.1. Asia Pacific Industrial Floor Coating, By Product
4.3.2. Asia Pacific Industrial Floor Coating, By Offering
4.3.3. Asia Pacific Industrial Floor Coating, By End User
4.3.4. By Country
4.3.4.1.1. China
4.3.4.1.2. Australia
4.3.4.1.3. Japan
4.3.4.1.4. South Korea
4.3.4.1.5. India
4.3.4.1.6. Rest of Asia Pacific
4.4. Rest of World
4.4.1. Rest of World Industrial Floor Coating, By Product
4.4.2. Rest of World Industrial Floor Coating, By Offering
4.4.3. Rest of World Industrial Floor Coating, By End User
The Plasma Fractionation Market has been segmented as below:
Plasma Fractionation Market, By Application
Plasma Fractionation Market, By Product
Plasma Fractionation Market, By End User
Plasma Fractionation Market, By Region
